Literature DB >> 12225360

All in the head: obstacles for immune rejection of brain tumours.

Paul R Walker1, Thomas Calzascia, Pierre-Yves Dietrich.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12225360      PMCID： PMC1782770          DOI： 10.1046/j.1365-2567.2002.01507.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  136 in total

1.  Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2.

Authors:  Y Sawamura; M Hosokawa; M C Kuppner; H Kobayashi; T Aida; H Abe; N de Tribolet
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

2.  Astrocytes induce blood-brain barrier properties in endothelial cells.

Authors:  R C Janzer; M C Raff
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

3.  Immunohistological study of mononuclear cell infiltrate in malignant gliomas.

Authors:  M L Rossi; J T Hughes; M M Esiri; H B Coakham; D B Brownell
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

4.  TWEAK stimulation of astrocytes and the proinflammatory consequences.

Authors:  P Saas; J Boucraut; P R Walker; A L Quiquerez; M Billot; S Desplat-Jego; Y Chicheportiche; P Y Dietrich
Journal:  Glia       Date:  2000-10       Impact factor: 7.452

5.  The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.

Authors:  P R Walker; T Calzascia; V Schnuriger; N Scamuffa; P Saas; N de Tribolet; P Y Dietrich
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

6.  Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.

Authors:  S Bodmer; K Strommer; K Frei; C Siepl; N de Tribolet; I Heid; A Fontana
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

7.  Specific cytotoxic activity of T lymphocyte clones derived from a patient with gliosarcoma.

Authors:  S Miyatake; H Kikuchi; K Iwasaki; J Yamashita; Z Y Li; Y Namba; M Hanaoka
Journal:  J Neurosurg       Date:  1988-11       Impact factor: 5.115

8.  Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Neurosurg       Date:  1987-08       Impact factor: 5.115

9.  Immunohistochemical analysis of tumor-infiltrating lymphocytes and major histocompatibility antigens in human gliomas and metastatic brain tumors.

Authors:  T Saito; R Tanaka; S Yoshida; K Washiyama; T Kumanishi
Journal:  Surg Neurol       Date:  1988-06

10.  Adult human glial cells can present target antigens to HLA-restricted cytotoxic T-cells.

Authors:  S Dhib-Jalbut; C V Kufta; M Flerlage; N Shimojo; H F McFarland
Journal:  J Neuroimmunol       Date:  1990 Sep-Oct       Impact factor: 3.478
View more
  18 in total

1.  Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies.

Authors:  Federico C F Calboli; David G Cox; Julie E Buring; J Michael Gaziano; Jing Ma; Meir Stampfer; Walter C Willett; Shelley S Tworoger; David J Hunter; Carlos A Camargo; Dominique S Michaud
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

Review 2.  Gammadelta T cells as immune effectors against high-grade gliomas.

Authors:  Lawrence S Lamb
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

3.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

4.  Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma.

Authors:  Niha Beig; Salendra Singh; Kaustav Bera; Prateek Prasanna; Gagandeep Singh; Jonathan Chen; Anas Saeed Bamashmos; Addison Barnett; Kyle Hunter; Volodymyr Statsevych; Virginia B Hill; Vinay Varadan; Anant Madabhushi; Manmeet S Ahluwalia; Pallavi Tiwari
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

Review 5.  Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

Authors:  Pawel Kalinski; Hideho Okada
Journal:  Semin Immunol       Date:  2010-04-20       Impact factor: 11.130

6.  Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.

Authors:  Nichole L Bryant; Catalina Suarez-Cuervo; G Yancey Gillespie; James M Markert; L Burt Nabors; Sreelatha Meleth; Richard D Lopez; Lawrence S Lamb
Journal:  Neuro Oncol       Date:  2009-02-11       Impact factor: 12.300

7.  Tumor necrosis factor α-induced hypoxia-inducible factor 1α-β-catenin axis regulates major histocompatibility complex class I gene activation through chromatin remodeling.

Authors:  Sadashib Ghosh; Arkoprovo Paul; Ellora Sen
Journal:  Mol Cell Biol       Date:  2013-05-13       Impact factor: 4.272

Review 8.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

Review 9.  Transforming growth factor-beta and its implication in the malignancy of gliomas.

Authors:  Laurent-Olivier Roy; Marie-Belle Poirier; David Fortin
Journal:  Target Oncol       Date:  2014-03-05       Impact factor: 4.493

Review 10.  Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper.

Authors:  Lara Driggers; Jian-Gang Zhang; Elizabeth W Newcomb; Lisheng Ge; Neil Hoa; Martin R Jadus
Journal:  J Neurooncol       Date:  2009-10-04       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.